Large language models (LLMs) are being deployed in hospitals to automatically identify adverse drug events from patient clinical notes, achieving accuracy rates between 70% and 90% on extraction tasks. This development could significantly reduce the time clinicians spend manually reviewing records for medication side effects and complications, while improving early detection of safety signals that might otherwise be missed .

What Are Adverse Events and Why Do Hospitals Struggle to Track Them?

Adverse events (AEs) are any unfavorable medical occurrences tied to healthcare interventions. Adverse drug events (ADEs) in particular, such as medication side effects and drug interactions, represent a major patient safety concern and drive significant healthcare costs . The challenge is that clinical narratives in electronic health records (EHRs) contain crucial information about these events, but much of it remains buried in free-text notes rather than structured data fields.

Manually identifying AEs from clinical notes is labor-intensive and error-prone. It requires clinicians to read through detailed progress notes, discharge summaries, and other documentation to spot patterns and complications. This manual process is both time-consuming and inconsistent, creating gaps in pharmacovigilance systems that monitor drug safety .

How Are AI Models Extracting Drug Side Effects from Medical Records?

Researchers have developed two main approaches for using LLMs to extract adverse events from clinical text. The first involves fine-tuning, where models pre-trained on large text datasets are further trained on annotated clinical notes to specialize in medical language. The second uses prompt-based information extraction, where models like GPT-4 or Llama are given natural-language instructions to identify and label events without extensive retraining .

Recent studies demonstrate impressive performance gains. Fine-tuned versions of LLaMA-3, a large language model developed by Meta, improved named-entity recognition and relation-extraction accuracy by 7 percentage points over earlier BERT-based models in low-data settings . Another team achieved approximately 90% exact-match accuracy extracting structured clinical data using a LoRA-fine-tuned LLaMA-3.1 model, approaching human expert performance .

The trade-off is computational cost. LLM inference can require 28 times more computing power and memory than traditional BERT models, making deployment in hospitals more expensive and complex .

What Do the Latest Benchmarks Show About Accuracy?

Performance metrics vary depending on the specific task. For named-entity recognition of adverse drug events, top-performing models achieve F1 scores (a measure combining precision and recall) ranging from 80% to 94% on standard datasets like the n2c2-2018 corpus of 505 discharge notes and the MADE 1.0 dataset containing 1,089 notes . Relation extraction, which identifies the connection between a drug and its side effect, is more challenging, with F1 scores typically ranging from 50% to 90% .

Zero-shot approaches, where models are given instructions without prior training on clinical data, can produce surprisingly good results on simpler extraction tasks. However, these approaches often struggle with specialized medical terminology and complex relationships between drugs and events .

Steps to Implement LLM-Based Adverse Event Extraction in Healthcare Settings

• Data Preparation: Preprocess clinical notes through de-identification to remove patient identifiers and ensure HIPAA compliance, then segment notes into relevant sections before feeding them to LLM systems.
• Model Selection: Choose between fine-tuned models for higher accuracy on institutional data or prompt-based approaches for faster deployment with lower computational overhead, depending on available resources and data volume.
• Integration and Validation: Connect the LLM system to existing EHR infrastructure, establish rigorous validation protocols with clinical experts, and implement safeguards to flag potential hallucinations or false positives before they reach clinicians.
• Monitoring and Maintenance: Continuously track model performance on new data, update systems as clinical terminology evolves, and maintain transparency about model limitations for physician trust and regulatory compliance.

Which Real-World Deployments Are Already Using This Technology?

Several organizations have begun implementing LLM-based adverse event extraction in clinical workflows. Pfizer launched a pilot program using LLMs to automate adverse event case report processing, demonstrating potential for accelerating pharmacovigilance at scale . Oncology departments have deployed real-time monitoring systems to track adverse events in cancer patients, while tools like Strata enable low-code fine-tuning of LLMs on institutional data for radiology and pathology report structuring .

These implementations show that LLMs can substantially reduce manual chart review burden and improve patient safety outcomes when properly validated and integrated into clinical workflows .

What Are the Key Challenges Holding Back Wider Adoption?

Despite promising results, several obstacles remain. Hallucination, where models generate plausible-sounding but false adverse events, poses a significant risk in clinical settings where accuracy is critical. Domain bias can cause models to miss rare or atypical presentations of drug side effects. Additionally, regulatory acceptance from agencies like the FDA and physician trust depend on rigorous validation, transparency about model limitations, and clear safeguards .

Computational costs also remain a barrier for smaller healthcare institutions. While fine-tuned models can achieve higher accuracy, they require substantial computing resources and expertise to maintain. Cloud-based APIs offer an alternative but raise privacy concerns when sensitive patient data must be transmitted outside institutional firewalls .

What's Next for AI-Powered Drug Safety Monitoring?

Future research directions include developing specialized biomedical LLMs trained specifically on medical literature and clinical data, exploring weakly supervised learning approaches that require less manual annotation, and creating hybrid human-AI workflows where models flag potential adverse events for clinician review rather than making autonomous decisions .

Multi-institutional collaborations using federated learning, where models are trained across multiple hospitals without centralizing sensitive data, could accelerate progress while preserving privacy. Real-time monitoring systems that continuously scan incoming clinical notes for emerging safety signals represent another promising frontier .

The ultimate promise is clear: by automating the labor-intensive process of adverse event detection, LLMs could enable earlier identification of safety signals, faster regulatory responses to emerging drug risks, and ultimately better patient outcomes across healthcare systems.